Literature DB >> 11779668

Low-dose oral naloxone reverses opioid-induced constipation and analgesia.

Maywin Liu1, Eric Wittbrodt.   

Abstract

The most common side effect of opioid therapy is constipation. It is often difficult to treat and is believed to be primarily a peripheral effect. Single large doses of oral naloxone have been shown to be efficacious in reversing opioid-induced constipation. However, they often cause the unwanted side effect of analgesia reversal. This study evaluated the effects on constipation and analgesia of low doses of oral naloxone given three times daily. Patients taking stable doses of opioids with complaints of constipation were recruited for this double-blind, randomized, placebo-controlled study. Patients were given 4 mg or 2 mg of oral naloxone, or placebo, three times daily. Stool frequency and symptoms related to constipation were recorded daily. Patients also recorded the daily amount of analgesics required to maintain pain control. Nine patients were recruited for the study. All the patients who received oral naloxone had some improvement in their bowel frequency. Three of the patients also experienced reversal of analgesia, including one who had complete reversal of analgesia. This study demonstrates that reversal of analgesia still occurred despite dividing the oral naloxone into very low doses relative to the total dose of opioid used. Patients using high doses of opioids appear to be the most vulnerable to the analgesic effect of oral naloxone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11779668     DOI: 10.1016/s0885-3924(01)00369-4

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  48 in total

1.  Effects of mu and kappa opioid receptor agonists and antagonists on contraction of isolated colon strips of rats with cathartic colon.

Authors:  Bao-Hua Liu; Ping Mo; Sheng-Ben Zhang
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

2.  [Strong opioids and constipation].

Authors:  A Schwarzer; F Nauck; E Klaschik
Journal:  Schmerz       Date:  2005-06       Impact factor: 1.107

3.  Inhibitory transmission in the bed nucleus of the stria terminalis in male and female mice following morphine withdrawal.

Authors:  Brennon R Luster; Elizabeth S Cogan; Karl T Schmidt; Dipanwita Pati; Melanie M Pina; Kedar Dange; Zoé A McElligott
Journal:  Addict Biol       Date:  2019-04-09       Impact factor: 4.280

Review 4.  Opioid-induced bowel dysfunction.

Authors:  Gyanprakash A Ketwaroo; Vivian Cheng; Anthony Lembo
Journal:  Curr Gastroenterol Rep       Date:  2013-09

Review 5.  Pathophysiology and management of opioid-induced constipation: European expert consensus statement.

Authors:  Adam D Farmer; Asbjørn M Drewes; Giuseppe Chiarioni; Roberto De Giorgio; Tony O'Brien; Bart Morlion; Jan Tack
Journal:  United European Gastroenterol J       Date:  2018-12-14       Impact factor: 4.623

Review 6.  New developments in the treatment of opioid-induced gastrointestinal symptoms.

Authors:  Jasper Pannemans; Tim Vanuytsel; Jan Tack
Journal:  United European Gastroenterol J       Date:  2018-08-27       Impact factor: 4.623

Review 7.  Pharmacological Treatment of Opioid-Induced Constipation Is Effective but Choice of Endpoints Affects the Therapeutic Gain.

Authors:  Salman Nusrat; Taseen Syed; Rabia Saleem; Shari Clifton; Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2018-10-03       Impact factor: 3.199

Review 8.  [Opioid-induced bowel dysfunction: a literature analysis on pathophysiology and treatment].

Authors:  Jürgen Osterbrink; Ute Haas
Journal:  Wien Med Wochenschr       Date:  2008

9.  Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.

Authors:  Oliver Löwenstein; Petra Leyendecker; Eberhard A Lux; Mark Blagden; Karen H Simpson; Michael Hopp; Björn Bosse; Karen Reimer
Journal:  BMC Clin Pharmacol       Date:  2010-09-29

10.  Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.

Authors:  A Sandner-Kiesling; P Leyendecker; M Hopp; L Tarau; J Lejcko; W Meissner; P Sevcik; M Hakl; R Hrib; R Uhl; H Dürr; K Reimer
Journal:  Int J Clin Pract       Date:  2010-03-29       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.